Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04570956 · ClinicalTrials.gov registry record · Phase 2
Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk
A Phase 2 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 2
- Development phase
- 65
- Enrollment target
NCT04570956: Clinical Trial Phase 2 study, sponsored by Mayo Clinic.
NCT04570956 is a Phase 2 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 65 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04570956, a Phase 2 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 65 participants
- Enrollment target
Study Summary
The investigators plan to prospectively study breast tissue changes after a short course of Tamoxifen (Tam).
Interventions
- DRUG Placebo
- OTHER Questionnaire Administration
- DRUG Tamoxifen
- DRUG Topical 4-OHT( 4-hydroxytamoxifen)gel 4 mg/each breast/day
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2021-07-26 |
| Est. Completion | 2024-10-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04570956
The ClinicalTrials.gov registry entry for NCT04570956 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT04570956 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04570956 about?
NCT04570956 is a clinical study titled "Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk". The investigators plan to prospectively study breast tissue changes after a short course of Tamoxifen (Tam).
What is the current status of trial NCT04570956?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2021-07-26. Estimated completion is 2024-10-15.
What interventions are being tested in trial NCT04570956?
The interventions under investigation include: Placebo (DRUG), Questionnaire Administration (OTHER), Tamoxifen (DRUG), Topical 4-OHT( 4-hydroxytamoxifen)gel 4 mg/each breast/day (DRUG).
Who is sponsoring clinical trial NCT04570956?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.